摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one

中文名称
——
中文别名
——
英文名称
(E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
英文别名
(E)-1-(4-chlorophenyl)-3-naphthalen-2-ylprop-2-en-1-one
(E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one化学式
CAS
——
化学式
C19H13ClO
mdl
——
分子量
292.765
InChiKey
BDQKQQMYIJJBSH-WUXMJOGZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    (E)-1-(4-chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one 在 1,1,2,2-tetrahydroperoxy-1,2-diphenylethane 、 potassium hydroxide 作用下, 以 1,4-二氧六环 为溶剂, 反应 1.3h, 以94%的产率得到
    参考文献:
    名称:
    1,1,2,2-四氢过氧-1,2-二苯乙烷作为强力固体氧化剂对α,β-不饱和酮的无金属高效环氧化
    摘要:
    1,1,2,2-四氢过氧1,2-二苯乙烷用于各种α,β-不饱和酮的高效无金属环氧化,在室温下于弱碱性条件下进行。
    DOI:
    10.1002/jccs.201700026
  • 作为产物:
    参考文献:
    名称:
    尿素-2,2-二氢过氧丙烷作为新型氧化剂,可轻松进行α,β-不饱和酮的环氧化
    摘要:
    摘要首次使用脲-2,2-二氢过氧丙烷作为氧源,成功地将各种芳香族α,β-不饱和酮转化为相应的环氧化物。反应在室温下在弱碱性条件下以高产率和短反应时间进行。 图形概要
    DOI:
    10.1007/s13738-016-0980-1
点击查看最新优质反应信息

文献信息

  • [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
    申请人:UNIV SAARLAND
    公开号:WO2010043711A1
    公开(公告)日:2010-04-22
    The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    该发明提供特定的小分子化合物,这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用,提供这些化合物的制备方法,包含这些化合物的药物组合物,以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
  • ALLOSTERIC PROTEIN KINASE MODULATORS
    申请人:Engel Matthias
    公开号:US20120046307A1
    公开(公告)日:2012-02-23
    The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    本发明提供了特定的小分子化合物,它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用,其生产方法,包含该化合物的药物组合物,以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
  • Metal-Free and Efficient Epoxidation of α,β-Unsaturated Ketones with 1,1,2,2-Tetrahydroperoxy-1,2-Diphenylethane as a Powerful Solid Oxidant
    作者:Kaveh Khosravi、Shirin Naserifar、Boshra Mahmoudi
    DOI:10.1002/jccs.201700026
    日期:2017.6
    1,1,2,2‐Tetrahydroperoxy‐1,2‐diphenylethane was used for the efficient and metal‐free epoxidation of various α,β‐unsaturated ketones, carried out under mild alkaline conditions at room temperature.
    1,1,2,2-四氢过氧1,2-二苯乙烷用于各种α,β-不饱和酮的高效无金属环氧化,在室温下于弱碱性条件下进行。
  • [EN] 2,3,5 TRISUBSTITUTED PYRROLE DERIVATIVES AS TOPOISOMERASE INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS TRISUBSTITUÉS 2, 3, 5 DE PYRROLE EN TANT QU'INHIBITEURS DE TOPOISOMÉRASE ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:UNIV OF MYSORE
    公开号:WO2017029684A1
    公开(公告)日:2017-02-23
    The compounds of Formula (1) having topoisomerase inhibitory effect includes [Formula should be inserted here] wherein, R1 is selected from a group consisting of H, OR5, optionally substituted C1-C12 alkyl, haloalkyl, C2-C12alkenyl, C2-C12alkynyl, C1-C12alkyloxy, C1-C12haloalkyloxy, C2-C10 heteroalkyl, C3- C12 cycloalkyl, C3-C12cycloalkenyl, C2- C12heterocycloalkyl, C2-C2 heterocycloalkenyl, C6-C18aryl, and C1-C18heteroaryl; R2, R3 and R4 are independently selected from a group consisting of H, halogen, CN, - NO2, SH, CF3, OH, CO2H, CONH2, OCF3, optionally substituted C1-C12alkyl, optionally substituted C1-C12haloalkyl optionally substituted C2-C12alkenyl, optionally substituted C2- C12alkynyl, optionally substituted C1-C12alkyloxy, optionally substituted C1- C12haloalkyloxy, optionally substituted C2-C12heteroalkyl, optionally substituted C3- C12cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted C2-C12 heterocycloalkyl, optionally substituted C2-C12 heterocycloalkenyl, optionally substituted C6- C18aryl, and optionally substituted C1-C18heteroaryl; R5 is selected H, optionally substituted C1-C12alkyl, optionally substituted C2- C12alkenyl, optionally substituted optionally substituted C1-C12 haloalkyl, optionally substituted C3-C12cycloalkyl, optionally substituted C6- C18aryl, and optionally substituted C1- Ci18heteroaryl; or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.
    具有拓扑异构酶抑制作用的Formula(1)化合物包括[在此插入公式]其中,R1从以下组中选择:H,OR5,可选择取代的C1-C12烷基,卤代烷基,C2-C12烯基,C2-C12炔基,C1-C12烷氧基,C1-C12卤代烷氧基,C2-C10杂基烷基,C3-C12环烷基,C3-C12环烯基,C2-C12杂环烷基,C2-C2杂环烯基,C6-C18芳基和C1-C18杂芳基;R2、R3和R4分别从以下组中选择:H,卤素,CN,-NO2,SH,CF3,OH,CO2H,CONH2,OCF3,可选择取代的C1-C12烷基,可选择取代的C1-C12卤代烷基,可选择取代的C2-C12烯基,可选择取代的C2-C12炔基,可选择取代的C1-C12烷氧基,可选择取代的C1-C12卤代烷氧基,可选择取代的C2-C12杂基烷基,可选择取代的C3-C12环烷基,可选择取代的C3-C12环烯基,可选择取代的C2-C12杂环烷基,可选择取代的C2-C12杂环烯基,可选择取代的C6-C18芳基,可选择取代的C1-C18杂芳基;R5选择为H,可选择取代的C1-C12烷基,可选择取代的C2-C12烯基,可选择取代的可选择取代的C1-C12卤代烷基,可选择取代的C3-C12环烷基,可选择取代的C6-C18芳基,可选择取代的C1-Ci18杂芳基;或其药学上可接受的盐、N-氧化物或前药。
  • Allosteric protein kinase modulators
    申请人:Universität des Saarlandes
    公开号:EP2177510A1
    公开(公告)日:2010-04-21
    The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    本发明提供了可异位调节 AGC 蛋白激酶和 Aurora 家族蛋白激酶活性或调节蛋白-蛋白相互作用的特异性小分子化合物、其生产方法、包含这些化合物的药物组合物,以及它们用于制备治疗和预防与 AGC 蛋白激酶或 Aurora 家族蛋白激酶异常活性相关疾病的药物的用途。
查看更多